Product Name:2-Amino-3-fluorobenzoic acid

IUPAC Name:2-amino-3-fluorobenzoic acid

CAS:825-22-9
Molecular Formula:C7H6FNO2
Purity:95%+
Catalog Number:CM109319
Molecular Weight:155.13

Packing Unit Available Stock Price($) Quantity
CM109319-25g in stock ǪǪ
CM109319-100g in stock ŮǸǸ

For R&D use only.

Inquiry Form

   refresh    

Product Details

CAS NO:825-22-9
Molecular Formula:C7H6FNO2
Melting Point:-
Smiles Code:C1=CC=C(C(=C1C(O)=O)N)F
Density:
Catalog Number:CM109319
Molecular Weight:155.13
Boiling Point:294.4°C at 760 mmHg
MDL No:MFCD01569395
Storage:Store at 2-8°C.

Category Infos

Benzenes
Benzene is an important organic compound with the chemical formula C6H6, and its molecule consists of a ring of 6 carbon atoms, each with 1 hydrogen atom. Benzene is a sweet, flammable, colorless and transparent liquid with carcinogenic toxicity at room temperature, and has a strong aromatic odor. It is insoluble in water, easily soluble in organic solvents, and can also be used as an organic solvent itself. The ring system of benzene is called benzene ring, and the structure after removing one hydrogen atom from the benzene ring is called phenyl. Benzene is one of the most important basic organic chemical raw materials. Many important chemical intermediates can be derived from benzene through substitution reaction, addition reaction and benzene ring cleavage reaction.

Column Infos

Carbonyl Compounds
In organic chemistry, a carbonyl group is a functional group with the formula C=O, composed of a carbon atom double-bonded to an oxygen atom, and it is divalent at the C atom. It is common to several classes of organic compounds (such as aldehydes, ketones and carboxylic acids), as part of many larger functional groups. A compound containing a carbonyl group is often referred to as a carbonyl compound.
Navacaprant
Navacaprant, a novel and selective kappa opioid receptor(KOR) antagonist, has no agonist properties implicated in opioid-related abuse.
Navacaprant is a potent KOR antagonist currently in clinical development for the treatment of neurobehavioral disorders, including Phase 3 clinical trials in adults with major depressive disorder. Navacaprant demonstrates high affinity and selectivity for the human KOR over the human MOR and DOR and exhibits reversible antagonist activity at KOR ex vivo and in vivo.